Litcius/Paper detail

Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness

Victor Mazereel, Johan Detraux, Davy Vancampfort, Ruud van Winkel, Marc D. Binder

2020Frontiers in Endocrinology193 citationsDOIOpen Access PDF

Abstract

People with serious mental illness (SMI), including schizophrenia, bipolar disorder, and major depressive disorder, have a higher mortality rate and shortened life expectancy. This is mainly attributable to physical diseases, particularly cardiovascular diseases (CVDs). Important risk factors for CVDs are obesity and other metabolic abnormalities, which are especially prevalent in people with SMI. Several factors contribute to this increased risk, including unhealthy lifestyles. Psychotropic medication independently further increases this risk. In this review we want to examine the relationship between obesity and other components of the metabolic syndrome and psychotropic medication in people with SMI.

Topics & Concepts

Metabolic syndromeMental illnessMedicineObesitySchizophrenia (object-oriented programming)PsychiatryBipolar disorderLife expectancyPsychotropic medicationAntipsychoticMental healthEnvironmental healthPopulationInternal medicineLithium (medication)Schizophrenia research and treatmentBipolar Disorder and TreatmentDiabetes Management and Research